EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitMetaanalyse

Risk of venous thromboembolism with upadacitinib in rheumatoid arthritis: a meta-analysis

Lang Qin, Lin-Jing Ye, Ping Liang, Lan-Qing Li, Yue-Fei Lu, Jie Lan, Ke-Dao Lai, Kang-Na Qin

Journal of Thrombosis and Thrombolysis · 27.07.2026

DOI: 10.1007/s11239-026-03373-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Thrombolysis, online erschienen am 27.07.2026. Verfasst von Lang Qin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Outpatient Department, Guangxi Institute of Chinese Medicine & Pharmaceutical Science, Dong-Ge Road No.20-1, Nanning, 530000, Guangxi, China. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Upadacitinib, a selective Janus kinase (JAK) inhibitor, has become an effective therapeutic option for rheumatoid arthritis (RA). However, venous thromboembolism (VTE) represents a potentially life-threatening complication associated with JAK inhibition, and uncertainties remain regarding the risk of specific VTE subtypes with upadacitinib, including non-fatal pulmonary embolism (nPE), non-fatal deep vein thrombosis (nDVT), and concurrent pulmonary embolism and deep vein thrombosis (cPE-DVT). This meta-analysis was performed to systematically assess the risks of these individual VTE subtypes in patients with RA receiving upadacitinib relative to comparator treatments. We systematically searched databases, including PubMed, Embase, and the Cochrane Library, for relevant randomized controlled trials (RCTs) in RA patients that reported VTE and its subtypes. Meta-analysis was conducted using the Mantel-Haenszel (M-H) fixed-effects model to calculate risk ratios (RR) with 95% confidence intervals (CI) due to low heterogeneity. A total of 4 RCTs involving 4201 patients were included in this meta-analysis. The results showed that no significant differences were observed between the upadacitinib and control groups in the risk of total VTE (0.79% vs. 0.78%; RR=0.93, 95%CI: 0.47-1.83, P=0.82), nPE (0.32% vs. 0.42%; RR=0.72, 95%CI: 0.28-1.83, P=0.49), nDVT (0.34% vs. 0.33%; RR=0.97, 95%CI: 0.32-2.96, P=0.96), or cPE-DVT (0.20% vs. 0.11%; RR=1.32, 95%CI: 0.20-8.62, P=0.77). Heterogeneity was absent across all analyses (I2 = 0% for all outcomes). In this meta-analysis of RCTs, upadacitinib did not demonstrate a significantly increased risk of VTE or its subtypes compared to controls in the studied RA population. Despite the low overall incidence and lack of signal in this cohort, the potential VTE risk highlighted by the FDA boxed warning necessitates careful patient selection based on comorbidities and dosage.

Schlagwörter

Stichwörter der Autor:innen

Deep vein thrombosisMeta-analysisPulmonary embolismRheumatoid arthritisUpadacitinibVenous thromboembolic event

Autor:innen und Institutionen

  • Outpatient Department, Guangxi Institute of Chinese Medicine & Pharmaceutical Science, Dong-Ge Road No.20-1, Nanning, 530000, Guangxi, China.
  • Department of Anesthesiology and Surgical Anesthesia, Guangxi Medical University College of Stomatology, Nanning, 530021, Guangxi, China.
  • Outpatient Department, Guangxi Institute of Chinese Medicine & Pharmaceutical Science, Dong-Ge Road No.20-1, Nanning, 530000, Guangxi, China. Laikedao2026@163.com.
  • Outpatient Department, The First Affiliated Hospital of Guangxi Medical University, Shuang-Yong Road No.6, Nanning, 530021, Guangxi, China. 759246325@qq.com.

Zitieren

APA

Qin, L., Ye, L. J., Liang, P., Li, L. Q., Lu, Y. F., Lan, J., Lai, K. D., & Qin, K. N. (2026). Risk of venous thromboembolism with upadacitinib in rheumatoid arthritis: a meta-analysis. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-026-03373-6

Vancouver

Qin L, Ye LJ, Liang P, Li LQ, Lu YF, Lan J, et al. Risk of venous thromboembolism with upadacitinib in rheumatoid arthritis: a meta-analysis. Journal of Thrombosis and Thrombolysis. 2026. doi:10.1007/s11239-026-03373-6

BibTeX
@article{Qin2026,
  author = {Qin, Lang and Ye, Lin-Jing and Liang, Ping and Li, Lan-Qing and Lu, Yue-Fei and Lan, Jie and Lai, Ke-Dao and Qin, Kang-Na},
  title = {Risk of venous thromboembolism with upadacitinib in rheumatoid arthritis: a meta-analysis},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2026},
  doi = {10.1007/s11239-026-03373-6}
}
Kostenlos starten →